Zymeworks Inc. ZYME 深 滬
等待開盤 02-11 09:30:00 美东时间
22.73
+0.220
+0.98%
華盛通- 最 高22.925
- 今 開22.79
- 成交量 49.01万股
- 最 低 22.25
- 昨 收 22.51
- 總市值 17.01亿
- 52周最高 28.49
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 9.03
- 委 比 -48.81%
- 總股本 7483.65万
- 歷史最高 59.03
- 量 比 0.86
- 振 幅 3.00%
- 歷史最低 4.11
- 每 手 1
- 風險率 5.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday
U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday Feb 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including KKR, Sirius XM Holdings Inc and Workday Inc on Tuesday. HIGHLIGHTS * KKR & CO Inc KKR.N : Jefferies cuts target price t
02-10 15:58
BRIEF-Halozyme Raises 2025 Revenue Estimates, Raises 2026 And Multi-Year Financial Guidance
BRIEF-Halozyme Raises 2025 Revenue Estimates, Raises 2026 And Multi-Year Financial Guidance Jan 28 (Reuters) - Halozyme Therapeutics Inc HALO.O : HALOZYME RAISES 2025 REVENUE ESTIMATES, RAISES 2026 AND MULTI-YEAR FINANCIAL GUIDANCE Source text: ID:nPn9RGHJja Further company coverage: HALO.O (( Reute
01-28 19:51
Zymeworks Inc. Joins Leerink Global Healthcare Conference for Fireside Chat
Zymeworks Inc. Joins Leerink Global Healthcare Conference for Fireside Chat Zymeworks Inc. will participate in the Citi's 2026 Virtual Oncology Leadership Summit with one-on-one meetings on February 18-19, 2026. The company will also attend the TD Cowen 46th Annual Health Care Conference, featuring
01-27 22:53
Zymeworks Announces Participation in Upcoming Investor Conferences
<p>Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company managing licensed healthcare assets and developing novel biotherapeutics, announces its management will participate in four upcoming investor conferences in 2026: Citi’s Virtual Oncology Summit (February 18-19), TD Cowen Conference (March 2 in Boston), Leerink Conference (March 9 in Miami), and Citizens Life Science Conference (March 11 in Miami). The company focuses on improving tr...
01-27 11:00
Zymeworks announce key mangement changes
Clinical-stage biotechnology company Zymeworks (ZYME) said that Dr. Sabeen Mekan has been promoted to senior VP and chief medical officer, effective February 1, 2026. Dr. Jeff Smith, current CMO, will...
01-12 20:32
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Zymeworks Inc. reported positive Phase 3 results for Ziihera® in HER2+ gastroesophageal adenocarcinoma and expects up to $440M in milestone payments for regulatory approvals in GEA across multiple markets. With strong financials, including $270.6M in cash and a $125M share repurchase plan, the company is well-positioned to execute its strategy focusing on royalty growth, R&D, and strategic acquisitions. Zymeworks also highlighted progress in its ...
01-11 23:00
Zymeworks Announces Results From Phase 3 HERIZON-GEA-01; Results Support Ziihera As The HER2-Targeted Agent-of-choice In HER2+ First-line Metastatic GEA And Ziihera Plus Chemotherapy To Replace Trastuzumab As The New Standard Of Care, With Or Without Tislelizumab Regardless Of PD-L1 Status
- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced positive efficacy
01-07 02:39
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Positive Phase 3 results for Ziihera in HER2+ gastroesophageal adenocarcinoma show improved survival and safety, supporting its potential as a new standard of care. Results to be presented at ASCO GI 2026. Zymeworks eligible for up to $440M in milestones.
01-06 18:34
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
